Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent ...

Regeneron beats quarterly estimates on eczema ... 2024 US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

The body then produces antibodies that can fight the coronavirus. Regeneron’s name might indicate that it’s a pharmaceutical company. However, Regeneron actually meets the definition of a ...

Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s websi Regeneron Pharmaceuticals, Inc. and Society ...